Results 231 to 240 of about 86,630 (338)
Abstract Continuous glucose monitoring (CGM) is now central to diabetes management, yet variation in how respective medical products are evaluated limits meaningful comparison between CGM systems. Three barriers currently constrain reliable interpretation of glucose‐derived measures.
John S. Pemberton +20 more
wiley +1 more source
Evaluation of microalbuminuria in type-2 diabetes mellitus under oral hypoglycemic agents: Association with age, sex, BMI, and renal clearance. [PDF]
Gnanasegaran S +5 more
europepmc +1 more source
Assessment of prescription pattern and cost effective analysis of oral hypoglycemic agents used in treatment of type 2 diabetes mellitus [PDF]
Maha George Manapurthu +3 more
openalex +1 more source
Abstract Aims Obesity is a growing global health crisis; pharmacotherapies such as tirzepatide combined with multidisciplinary lifestyle support have shown promise but real‐world evidence in digital weight‐loss services (DWLSs) is limited. This retrospective study evaluated 6‐ and 12‐month weight loss, adherence and predictors of outcomes in an ...
Louis Talay +3 more
wiley +1 more source
Studies on lndan Acids as Potential Oral Hypoglycemic Agents.
SAMIR CH. LAHIRI, JAYANTA K. GUPTA
openalex +1 more source
Abstract Glucocorticoids (GCs) are widely utilised for the treatment of inflammatory and autoimmune conditions but often precipitate significant hyperglycaemia. People with type 1 diabetes (PWT1D) may be particularly affected due to the challenges of adjusting insulin dosing, for which recommendations remain unclear.
Alexandra Katz +8 more
wiley +1 more source
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino +14 more
wiley +1 more source

